188577-70-0

Basic information

• Product Name: N-(4-CHLORO-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE
• Synonyms: N-(4-CHLORO-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE;N-(4-CHLOROPYRIDIN-2-YL)PIVALAMIDE
• CAS NO: 188577-70-0
• Molecular Formula: C₁₀H₁₃ClN₂O
• Molecular Weight: 212.68
• Mol File: 188577-70-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 365.346°C at 760 mmHg
• Flash Point: 174.755°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(4-CHLORO-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-CHLORO-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE(188577-70-0)
• EPA Substance Registry System: N-(4-CHLORO-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE(188577-70-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 188577-70-0(Hazardous Substances Data)

Usage

General Description

N-(4-chloro-pyridin-2-yl)-2,2-dimethyl-propionamide is a chemical compound that belongs to the class of amides. It is a white solid in appearance and is soluble in organic solvents. N-(4-CHLORO-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE is commonly used as a building block or intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. Its structure and properties make it valuable in the development of new compounds with potential biological and industrial applications. Additionally, it is important to handle this compound with care as it may pose risks to human health and the environment if not properly managed.

InChI:InChI=1/C10H13ClN2O/c1-10(2,3)9(14)13-8-6-7(11)4-5-12-8/h4-6H,1-3H3,(H,12,13,14)

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 3282-30-2 pivaloyl chloride 
• 26452-80-2 2,4-dichloropyridine 
• 754-10-9 2,2-dimethylpropionamide 

Downstream Products

• 188577-71-1 N-(4,5-dichloropyridin-2-yl)-2,2-dimethylpropanamide 
• 188577-68-6 4,5-dichloro-2-aminopyridine 
• 749925-46-0 N-(4-chloro-3-formylpyridin-2-yl)-2,2-dimethylpropanamide 
• 1203510-02-4 N-(3-benzoyl-4-chloropyridin-2-yl)-2,2-dimethylpropanamide 
• 662116-67-8 4,5-dichloro-3-nitropyridin-2-ylamine 
• 1446244-52-5 N-(3-((2-amino-5-chloro-3-nitropyridin-4-yl)oxy)phenyl)acrylamide 
• 1446244-53-6 N-(3-((2,3-diamino-5-chloropyridin-4-yl)oxy)phenyl)acrylamide 
• 1446244-32-1 N-(3-(6-chloro-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yloxy)phenyl)acrylamide 
• 662116-66-7 2,3-diamino-4,5-dichloropyridine 
• 1137477-57-6 N₄-(1-methylpiperidin-4-yl)-5-phenylpyridine-2,4-diamine 
• 1137477-72-5 tert-butyl 4-(2-amino-5-(4-methoxyphenyl)pyridin-4-ylamino)piperidine-1-carboxylate 
• 1137477-58-7 5-(4-(1-methylpiperidin-4-ylamino)-5-phenylpyridin-2-ylamino)pyrazine-2-carbonitrile 
• 1137477-93-0 tert-butyl 4-((2-amino-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)piperidine-1-carboxylate 
• 1137477-75-8 5-(5-(4-methoxyphenyl)-4-(piperidin-4-ylamino)pyridin-2-ylamino)pyrazine-2-carbonitrile 

Relevant articles and documents

Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-RafV600E inhibitors

B-RafV600E was an effective target for the treatment of human cancers. Based on a pan-Raf inhibitor TAK-632, a series of N-(4-aminopyridin-2-yl)amide derivatives were designed as novel B-RafV600E inhibitors. Detailed structure-activi

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention discloses compounds useful in treatment of conditions associated with excessive activity of transforming growth factor beta (TGF-β), particularly type 1 or activin-like kinase 5 (ALK 5). Specifically the present invention discloses compound of formula (I) which exhibit inhibitory activity against ALK 5. Method of treating conditions associated with excessive activity (ALK 5) with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a